Artwork

Content provided by American Medical Association and JAMA Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Medical Association and JAMA Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

Risankizumab for Ulcerative Colitis

15:49
 
Distribuie
 

Manage episode 430197887 series 32410
Content provided by American Medical Association and JAMA Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Medical Association and JAMA Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Ulcerative colitis can significantly decrease quality of life. A third of patients have persistent symptoms with tumor necrosis factor inhibitors and nearly 1 in 5 patients will be hospitalized within 5 years of diagnosis. Author Gilaad G. Kaplan, MD, MPH, of the University of Calgary joins JAMA Associate Editor John M. Inadomi, MD, to discuss Risankizumab for Ulcerative Colitis. Related Content:

  continue reading

825 episoade

Artwork
iconDistribuie
 
Manage episode 430197887 series 32410
Content provided by American Medical Association and JAMA Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Medical Association and JAMA Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

Ulcerative colitis can significantly decrease quality of life. A third of patients have persistent symptoms with tumor necrosis factor inhibitors and nearly 1 in 5 patients will be hospitalized within 5 years of diagnosis. Author Gilaad G. Kaplan, MD, MPH, of the University of Calgary joins JAMA Associate Editor John M. Inadomi, MD, to discuss Risankizumab for Ulcerative Colitis. Related Content:

  continue reading

825 episoade

모든 에피소드

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință